Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
Monday, June 03, 2024CStone Pharmaceuticals an innovationdriven biopharmaceutical company focused on the research and development
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Monday, June 03, 2024Werewolf Therapeutics Inc an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate
Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT®▼ (amivantamab)
Saturday, June 01, 2024JanssenCilag International NV a Johnson Johnson company announced today the submission of an application for the extension of the RYBREVANT
Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®
Friday, May 31, 2024Vanda Pharmaceuticals Inc today announced that ownership of the US New Drug Application and Investigational New Drug Applications for PONVORY has been transferred to Vanda from a Johnson Johnson Company
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
Friday, May 31, 2024Candel Therapeutics Inc a clinicalstage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that the US Food and Drug Administration
Incyte Completes Acquisition of Escient Pharmaceuticals
Friday, May 31, 2024Incyte today announced that it has completed its acquisition of Escient Pharmaceuticals a clinicalstage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuroimmune disorders The acquisition o...
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
Friday, May 31, 2024Biogen Inc announced the European Commission has granted marketing authorization under exceptional circumstances and maintained orphan
JJP Biologics Announces Decision to Conduct First-in-Human Clinical Trials for Anti-Inflammatory Monoclonal Antibody JJP-1212 (Anti-CD89)
Thursday, May 30, 2024JJP Biologics a privately held biopharmaceutical company developing innovative antibodybased therapies announced the European Medicines Agency
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
Thursday, May 30, 2024Milestone Pharmaceuticals Inc a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines today announced that the United States Food and Drug Administration
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
Thursday, May 30, 2024Rocket Pharmaceuticals Inc a fully integrated latestage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high
